Acetaminophen Market Opportunity, Growth Drivers, Industry Trend Analysis, And Forecast 2025-2034

(MENAFN- GlobeNewsWire - Nasdaq) Increasing Chronic Pain & Self-Care Trends Propel Global Acetaminophen Demand: North America Leads with a 43.2% Market Share

Dublin, Sept. 26, 2025 (GLOBE NEWSWIRE) -- The "Acetaminophen Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034" report has been added to ResearchAndMarkets's offering.
The Global Acetaminophen Market was valued at USD 10.4 billion in 2024 and is estimated to grow at a CAGR of 4.5% to reach USD 16.6 billion by 2034.

The rising prevalence of chronic pain conditions and recurring fever across various age groups continues to propel the demand for acetaminophen worldwide. As a widely accessible and trusted over-the-counter drug, acetaminophen is commonly used for mild to moderate pain and fever management. The global uptick in cases of infectious illnesses and headache-related disorders is further accelerating demand. As a non-opioid analgesic and antipyretic, acetaminophen remains a first-line treatment option, especially for patients intolerant to NSAIDs due to gastrointestinal or cardiovascular issues. The market growth is also reinforced by an increasing reliance on self-care and non-prescription medications across many regions.

Leading players such as Sun Pharmaceutical Industries, Abbott, Teva Pharmaceuticals, Sanofi, and Aurobindo Pharma play a critical role by offering a diverse range of formulations, leveraging extensive supply chains, and maintaining strong brand recognition in both developed and emerging economies. These companies continuously invest in production scalability, ensuring consistent availability of acetaminophen across various therapeutic segments. Their deep regulatory expertise allows for smoother product approvals, while global manufacturing footprints help mitigate supply disruptions. In addition to focusing on generics, they also differentiate themselves by introducing extended-release versions, pediatric-friendly formats, and combination therapies that improve patient compliance.
In 2024, the tablet-based formulations segment held a 65.1% share. This dominance is attributed to their cost-effectiveness, ease of manufacturing, and consumer preference for consistent dosage formats. Tablets are widely preferred for their longer shelf life, portability, and compatibility with large-scale production, especially for over-the-counter products. With broad accessibility in retail pharmacies and supermarkets, the oral tablet remains the go-to form for most users across adult and pediatric populations. Strong demand from both urban and rural healthcare settings, combined with robust pharmaceutical manufacturing capacities, continues to sustain the segment's leadership.
The oral route segment held a 90.4% share in 2024. Oral formulations - including capsules, syrups, and tablets - remain the preferred choice due to their ease of administration, rapid availability in the body, and suitability for at-home treatment. These formats support self-medication trends and are especially effective for treating low to moderate pain or fever without the need for professional supervision. Additionally, enhanced oral formulations such as chewables, extended-release variants, and child-friendly syrups are improving patient experience and ensuring better adherence across age groups.
North America Acetaminophen Market with a 43.2% share in 2024. The region's high consumption is linked to the widespread prevalence of musculoskeletal conditions such as arthritis and chronic back pain, coupled with an increased reliance on non-prescription medications for everyday ailments. Moreover, awareness campaigns and healthcare policies promoting alternatives to opioids have further established acetaminophen as a preferred option. With robust public health infrastructure, high consumer awareness, and strong pharmaceutical presence, North America continues to drive significant revenue growth and innovation in the sector.
Some of the top companies operating in the Acetaminophen Market include Hyloris Pharmaceuticals, Granules India Limited, B. Braun Melsungen, Bayer AG, Dr. Reddy's Laboratories, Mallinckrodt Pharmaceuticals, Novartis, GlaxoSmithKline Pharmaceuticals, Lupin, Alkem Laboratories, and Kenvue (Johnson & Johnson), alongside others like Sanofi and Convergent Technologies. To strengthen their position in the acetaminophen market, leading players are adopting several key strategies.

Many companies focus on portfolio diversification by introducing a broad range of formulations tailored to specific patient needs, such as pediatric drops, effervescent tablets, and combination products. Strong emphasis is placed on manufacturing scalability and cost optimization to improve accessibility in developing regions. Investments in supply chain efficiency and strategic partnerships with retail distributors further ensure product availability. In addition, companies continue to engage in marketing initiatives to enhance brand recall and differentiate their acetaminophen products. Compliance with evolving regulatory frameworks and investment in product quality, safety, and clinical efficacy remain essential elements of their long-term market strategy.
Key Attributes:

Report Attribute	Details
No. of Pages	130
Forecast Period	2024 - 2034
Estimated Market Value (USD) in 2024	$10.4 Billion
Forecasted Market Value (USD) by 2034	$16.6 Billion
Compound Annual Growth Rate	4.5%
Regions Covered	Global

Key Topics Covered:
Chapter 1 Methodology and Scope
1.1 Market scope and definition
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Data mining sources
1.3.1 Global
1.3.2 Regional/Country
1.4 Base estimates and calculations
1.4.1 Base year calculation
1.4.2 Key trends for market estimation
1.5 Primary research and validation
1.5.1 Primary sources
1.6 Forecast model
1.7 Research assumptions and limitations
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
2.2 Key market trends
2.2.1 Regional trends
2.2.2 Dosage form trends
2.2.3 Route of administration trends
2.2.4 Application trends
2.2.5 Distribution channel trends
2.3 CXO perspectives: Strategic imperatives
2.3.1 Key decision points for industry executives
2.3.2 Critical success factors for market players
2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising cases of common cold, fever, and influenza
3.2.1.2 Rising number of chronic diseases and pain management conditions
3.2.1.3 Increasing use of intravenous paracetamol in combination with NSAIDs and narcotics
3.2.2 Industry pitfalls and challenges
3.2.2.1 Side effects of paracetamol, such as a rise in blood pressure and hepatotoxicity
3.2.2.2 Availability of more effective painkillers
3.2.3 Market opportunities
3.2.3.1 Expansion into emerging markets
3.2.3.2 Development of innovative and safer formulations
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Reimbursement scenario
3.6 Future market trends
3.7 Gap analysis
3.8 Pipeline analysis
3.9 Porter's analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2024
4.1 Introduction
4.2 Company market share analysis
4.2.1 North America
4.2.2 Europe
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Key developments
4.6.1 Mergers and acquisitions
4.6.2 Partnerships and collaborations
4.6.3 New product launches
4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, by Dosage Form, 2021-2034 ($ Mn)
5.1 Key trends
5.2 Tablet
5.3 Liquid suspension
5.4 Infusion solution
5.5 Other dosage forms
Chapter 6 Market Estimates and Forecast, by Route of Administration, 2021-2034 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
6.4 Other routes of administration
Chapter 7 Market Estimates and Forecast, by Application, 2021-2034 ($ Mn)
7.1 Key trends
7.2 Pain relief and fever
7.3 Common cold
7.4 Headache
7.5 Abdominal cramps
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2021-2034 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, by Region, 2021-2034 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
Chapter 10 Company Profiles
10.1 Abbott
10.2 Alkem Laboratories
10.3 Aurobindo Pharma
10.4 B. Braun Melsungen
10.5 Bayer AG
10.6 Dr. Reddy's Laboratories
10.7 GlaxoSmithKline Pharmaceuticals
10.8 Granules India Limited
10.9 Hyloris Pharmaceuticals
10.10 Kenvue (Johnson & Johnson)
10.11 Lupin
10.12 Mallinckrodt Pharmaceuticals
10.13 Novartis
10.14 Sanofi
10.15 Sun Pharmaceutical Industries
10.16 Teva Pharmaceuticals

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

• Acetaminophen Market

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN26092025004107003653ID1110114594